Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0000950170-25-028351
Filing Date
2025-02-27
Accepted
2025-02-27 07:11:50
Documents
17
Effectiveness Date
2025-02-27

Document Format Files

Seq Description Document Type Size
1 S-8 cgem-20250227.htm S-8 107587
2 EX-5.1 cgem-ex5_1.htm EX-5.1 11830
3 EX-23.2 cgem-ex23_2.htm EX-23.2 7109
4 EX-FILING FEES cgem_exfilingfees.htm   iXBRL EX-FILING FEES 39005
5 GRAPHIC img108548027_0.jpg GRAPHIC 3038
6 GRAPHIC img133713030_0.jpg GRAPHIC 3027
  Complete submission text file 0000950170-25-028351.txt   327524

Data Files

Seq Description Document Type Size
19 EXTRACTED XBRL INSTANCE DOCUMENT cgem_exfilingfees_htm.xml XML 14451
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

EIN.: 813879991 | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-285302 | Film No.: 25672974
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)